Japanese progress for ridaforolimus
This article was originally published in Scrip
Executive Summary
Banyu, Merck & Co's Japanese subsidiary, has begun recruiting for a Phase II trial with ridaforolimus (MK-8669), marking a step forward in the local development programme for the anticancer.